Docetaxel therapy for angiosarcoma(Stewart-Treves syndrome)

Docetaxel therapy for angiosarcoma(Stewart-Treves syndrome) - Docetaxel for Stewart-Treves syndrome

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003242

Enrollment

Registered

2010-02-24

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stewart-Treves syndrome

Interventions

tri-weekly docetaxele

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Stewart-Treves syndrome having (or highly suspicious of) metastases

Exclusion criteria

Exclusion criteria: 1 Allergy to Docetaxele or the component 2 Infectious disease 3 Severe liver, kidney, heart, gastro-intestinal, bone marrow injury 4 Pregnant or feeding 5 Concidered not suitable for the study

Design outcomes

Primary

Measure	Time frame
phisical examination, chest X-ray, CT scan	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026